Watch and Wait – Actualities in the Treatment of Chronic Lymphocytic Leukemia

1. SEER Cancer Statistics Review (CSR), 1975-2011. Available at: seer.cancer.gov/csr/1975_2011/Search in Google Scholar

2. Scarfò L, Ferreri AJM, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-182.10.1016/j.critrevonc.2016.06.003Open DOISearch in Google Scholar

3. Hallek M, Pflug N. Chronic lymphocytic leukemia. Annals of Oncology. 2010;21:vii154–vii164.10.1093/annonc/mdq373Search in Google Scholar

4. Hallek M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90:446-460.10.1002/ajh.23979Search in Google Scholar

5. Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946-965.10.1002/ajh.24826Search in Google Scholar

6. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008;111:5446-5456.10.1182/blood-2007-06-093906Search in Google Scholar

7. Scarfò L, Ferreri AJM, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol Hematol. 2016;104:169-182.10.1016/j.critrevonc.2016.06.003Open DOISearch in Google Scholar

8. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990-4997.10.1182/blood.V87.12.4990.bloodjournal87124990Search in Google Scholar

9. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219-234.10.1182/blood.V46.2.219.219Search in Google Scholar

10. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198-206.10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-VSearch in Google Scholar

11. Riwa S, Marcel M. Chronic Lymphocytic Leukemia (CLL): Upfront Treatment Options in 2017. Hematol Transfus Int J. 2017;4:00076.Search in Google Scholar

12. Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99:965-972.10.3324/haematol.2013.096107Search in Google Scholar

13. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079-4088.10.1200/JCO.2005.12.051Open DOISearch in Google Scholar

14. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164-1174.10.1016/S0140-6736(10)61381-5Search in Google Scholar

15. Tam CS, O’Brien S, Wierda W, et al. Long-term results of the fludarabine: cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112:975-980.10.1182/blood-2008-02-140582Search in Google Scholar

16. Strati P, Keating MJ, O’Brien SM, Burger J, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123:3727-3732.10.1182/blood-2013-11-538116Search in Google Scholar

17. Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2012;30:3209-3216.10.1200/JCO.2011.39.2688Open DOISearch in Google Scholar

18. Eichhorst B, Fink AM, Busch R, et al. Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) versus Bendamustine and Rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 Trial, an international, randomized study of the german CLL Study Group (GCLLSG). Blood. 2013;122:Suppl.21:abstract 526.10.1182/blood.V122.21.526.526Search in Google Scholar

19. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101-1110.10.1056/NEJMoa1313984Search in Google Scholar

20. Hillmen P, Robak T, Janssens A, et al. Ofatumumab + Chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukemia (CLL): results of the phase III study complement 1 (OMB110911). Blood. 2013;122:Suppl21:abstract 528.10.1182/blood.V122.21.528.528Search in Google Scholar

21. Foon KA, Boyiadzis M, Land SR, et al. Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2009;27:498-503.10.1200/JCO.2008.17.2619Open DOISearch in Google Scholar

22. O’Brien S, Furman RR, Coutre SE, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase1b/2 trial. Lancet Oncol. 2014;15:48-58.10.1016/S1470-2045(13)70513-8Search in Google Scholar

23. Byrd JC, O’Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:1278-1279.10.1056/NEJMoa1215637Search in Google Scholar

24. Brown JR, O’Brien S, Barrientos JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213-223.10.1056/NEJMoa1400376Search in Google Scholar

25. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib: an inhibitor of phosphatidylinositol 3-kinase p110 delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390-3397.10.1182/blood-2013-11-535047Search in Google Scholar

26. Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib: a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406-3413.10.1182/blood-2013-11-538546Search in Google Scholar

27. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997-1007.10.1056/NEJMoa1315226Search in Google Scholar

28. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011;12:1204-1213.10.1016/S1470-2045(11)70242-XOpen DOISearch in Google Scholar

29. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia. 2008;22:2048-2053.10.1038/leu.2008.214528928318754025Open DOISearch in Google Scholar

30. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749-1755.10.1200/JCO.2009.25.3187497910120194866Open DOISearch in Google Scholar

31. Montserrat E, Gribben JG. Autografting CLL: the game is over. Blood. 2011;117:6057-6058.10.1182/blood-2011-04-34409321659550Search in Google Scholar

32. Sutton L, Chevret S, Tournilhac O, et al. Autologous stem cell transplantation as first-line treatment strategy for chronic lymphocytic leukemia: a multicentre, randomized, controlled trial from the SFGM-TC and GFLLC. Blood. 2011;117:6109-6119.10.1182/blood-2010-11-31707321406717Search in Google Scholar

33. Magni M, Di Nicola M, Patti C, et al. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis. Bone Marrow Transplant. 2014;49:485-491.10.1038/bmt.2013.21424442244Search in Google Scholar

34. Dreger P, Schetelig J, Andersen N, et al. Managing high risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014;124:3841-3849.Search in Google Scholar